A technology firm, specializing in tools to enhance MR images, has ballooned its fundraising to $140 million, leaders announced Wednesday.
Perspectum’s latest contribution totals $19 million, with brokerage and investment bank Oppenheimer & Co. pitching in the lion’s share. Headquartered in Oxford, United Kingdom, the firm’s flagship product is a noninvasive MRI tool used to help physicians accurately assess for the signs of liver disease.
Since 2021, more than 77 million U.S. adults covered by Medicare and commercial plans have had access to LiverMultiScan, Perspectum said in an announcement. Coverage from both public and private plans has led to adoption in “several major” U.S. hospitals.
“The funding supports a more accelerated approach as Perspectum moves to achieve its ultimate goal of standardizing the use of integrated AI clinical decision support tools for the management of patient health at scale globally,” Board Chair Michael Rosenblatt, MD, said in a statement.
Perspectum said it will seek to expand its footprint across the U.S. following the funding news, along with accelerating the development of products in oncology and related to other organs.
The company said its software products work by enhancing the capabilities of standard MRI, enabling the modality to capture multiparametric mapping data. This allows artificial intelligence-based software to more precisely measure organ inflammation, bolstering doctors’ ability to monitor and diagnose diseases.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.